A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.
Completed
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3
2003-03-01
The purpose of this study is to determine if adding extended-release galantamine
hydrobromide, compared with adding placebo, to current atypical antipsychotic therapy is well
tolerated and effective in improving cognitive impairment in patients with schizophrenia.
The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type
Completed
Janssen Korea, Ltd., Korea
Phase 4
2004-03-01
The purpose of this study is to assess the efficacy of galantamine on the attention of
patients with Alzheimer's Disease, how an improvement of attention of Alzheimer's Disease
patients affects their activities of daily living, and the global benefit of galantamine.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
